Regenerative Medical Technology Group Inc. engages in the stem cell therapy business in the United States and internationally. It provides CELLGENIC FLOW EXOSOMES for hair loss and pain management; CELLGENIC Mesenchymal Stem Cell, which excretes growth factors, cytokines, and proteins for regeneration of tissue; CELLGENIC LYOPHILIZED EXOSOMES that is derived from human umbilical cord mesenchymal stem cells, including potent growth factors, peptides, coenzymes, minerals, amino acids, vitamins and UV radiation reducing agents for skin revitalization; and VITANOVAS that offers in-home treatments to patients in need of immune modulation to help fight infections, viruses, and diseases. The company also offers GCELL, a closed-system medical device to harness the natural and restorative capabilities of adipose tissue; CELLGENIC SVF, an isolation kit system that has the ingredients and consumables for the extraction of adipose-derived stem cells from fat; CELLGENIC BONE MARROW; CELLGENIC Platelet Rich Plasma for healing and reducing inflammation; CELLGENIC HUMAN PLACENTA; and CELLGENIC ALLOGENEIC PRP. In addition, it is involved in the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic; development of proprietary cell therapy products; and provision of cell collection, cell storage, and training services to physicians. The company was formerly known as Meso Numismatics, Inc. and changed its name to Regenerative Medical Technology Group Inc. in May 2024. Regenerative Medical Technology Group Inc. was incorporated in 1999 and is based in Boca Raton, Florida.